Koers Surgical Science Sweden AB (publ) Nasdaq Stockholm
Aandelen
SE0014428512
Geavanceerde medische apparatuur & technologie
Omzet 2024 * | 999 mln. 92,41 mln. 85,85 mln. | Omzet 2025 * | 1,2 mld. 111 mln. 103 mln. | Marktkapitalisatie | 7,86 mld. 727 mln. 675 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 212 mln. 19,6 mln. 18,21 mln. | Nettowinst (verlies) 2025 * | 304 mln. 28,11 mln. 26,11 mln. | EV/omzet 2024 * | 7 x |
Nettoliquiditeiten 2024 * | 863 mln. 79,77 mln. 74,1 mln. | Nettoliquiditeiten 2025 * | 1,13 mld. 105 mln. 97,41 mln. | EV/omzet 2025 * | 5,62 x |
K/w-verhouding 2024 * |
37
x | K/w-verhouding 2025 * |
25,9
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 73,33% |
Recentste transcriptie over Surgical Science Sweden AB (publ)
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Anders Larsson
FOU | Founder | 51 | 24-07-97 |
Gisli Hennermark
CEO | Chief Executive Officer | 52 | 01-01-15 |
Director of Finance/CFO | 54 | 01-01-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Roland Bengtsson
CHM | Chairman | 69 | 01-01-05 |
Director/Board Member | 57 | 01-01-17 | |
Director/Board Member | 49 | 12-05-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+5,70% | 32,88 mld. | |
+18,46% | 7,84 mld. | |
+22,71% | 3,95 mld. | |
-17,95% | 3,11 mld. | |
-19,93% | 1,38 mld. | |
-30,65% | 1,21 mld. | |
+4,36% | 933 mln. | |
-34,81% | 911 mln. | |
-26,60% | 829 mln. |